AbCellera Biologics logo

AbCellera Biologics

ABCL | NASDAQ
Chart Builder DCF Calculator
$11.12
-$0.37 (-3.22%)
At close: Nov 16, 2026, 4:00 PM ET
$11.13
+$0.01 (+0.09%)
After-hours: Nov 16, 2026, 7:53 PM ET
-3.22%

Rating

Updated: Nov 16, 2026
32.4
-2.0 pts
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #736/1021 (Top 72%)

Key Statistics

Market Data

Market Cap $3.63B
1D Range
11.03 11.44
52W Range
2.78 14.82

Valuation (TTM)

PE -23.17
PB 3.42
EV/EBITDA -21.65

Valuation (NTM)

Forward PE N/A
Forward PEG -6.17
Price Target $18.00
Loading financial charts...

Profile

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems ...

Sector Healthcare
Industry Biotechnology
Employees 562
IPO Date Dec 11, 2020
Fiscal Year January - December

Latest News

AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment

9 hours ago · marketbeat.com

AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

3 days ago · seekingalpha.com

AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

4 days ago · zacks.com

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

4 days ago · marketbeat.com

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call

7 days ago · marketbeat.com

What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

7 days ago · zacks.com

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

1 month ago · businesswire.com

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

2 months ago · businesswire.com

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

2 months ago · zacks.com

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

Earnings

Latest Earnings
Nov 9, 2026
EPS
-$0.13
Beat +23.82%
REV
$10.64M
Beat +26.41%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
5
Consensus
Buy
Price Target
$18.00
Upside
+61.87%
Buy (5)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.